Press release
Peripheral T Cell Lymphomas Pipeline Assessment 2024: Therapies, Clinical Trials, and Key Companies Involved by DelveInsight | Celleron Therapeutics, Myeloid Therapeutics, Astex Pharma, Citius Pharma
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Peripheral T Cell Lymphomas pipeline constitutes 40+ key companies continuously working towards developing 40+ Peripheral T Cell Lymphomas treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.The Peripheral T Cell Lymphomas Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
"Peripheral T Cell Lymphomas Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphomas-ptcl-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Peripheral T Cell Lymphomas Market.
Some of the key takeaways from the Peripheral T Cell Lymphomas Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Peripheral T Cell Lymphomas treatment therapies with a considerable amount of success over the years.
*
Peripheral T Cell Lymphomas companies working in the treatment market are HUYA Bioscience International, Applied Therapeutics, Autolus, Akeso Biopharma, Astex Pharmaceuticals, Secura Bio, Innate Pharma, Dizal Pharmaceutical, CSPC ZhongQi Pharmaceutical Technology, and others, are developing therapies for the Peripheral T Cell Lymphomas treatment
*
Emerging Peripheral T Cell Lymphomas therapies in the different phases of clinical trials are- HBI-8000, AT-104, Auto 5, AK 104, Tolinapant, Duvelisib, Lacutamab, AZD 4205, Mitoxantrone liposomal, and others are expected to have a significant impact on the Peripheral T Cell Lymphomas market in the coming years.
*
In December 2024, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced new data showcasing significant improvements in quality of life for patients with cutaneous T-cell lymphoma (CTCL) treated with lacutamab in the TELLOMAK Phase 2 clinical study. The findings were presented at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, California.
*
In December 2024, Secura Bio, Inc. (Secura Bio), an integrated pharmaceutical company focused on the global development and commercialization of effective oncology therapies, presented two posters at the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego, CA. The first poster showcased new data from the Company's Phase 2 PRIMO trial of duvelisib for treating relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL), while the second poster outlined the clinical design for the planned Phase 3 randomized trial of duvelisib in R/R nodal T-follicular helper cell lymphoma (TERZO Trademark ).
Peripheral T Cell Lymphomas Overview
Peripheral T-cell lymphomas (PTCL) are a diverse group of aggressive blood cancers that develop in T-cells, a type of white blood cell involved in immune function. Unlike other types of lymphoma, PTCL originates outside the bone marrow, typically in lymph nodes, spleen, or other tissues. Symptoms may include swollen lymph nodes, fever, weight loss, night sweats, and skin rashes. PTCL is rare and often more difficult to treat compared to other lymphomas. Treatment options may include chemotherapy, immunotherapy, stem cell transplants, and targeted therapies, depending on the specific subtype and stage of the disease.
Get a Free Sample PDF Report to know more about Peripheral T Cell Lymphomas Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/peripheral-t-cell-lymphomas-ptcl-pipeline-insight [https://www.delveinsight.com/report-store/peripheral-t-cell-lymphomas-ptcl-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Peripheral T Cell Lymphomas Drugs Under Different Phases of Clinical Development Include:
*
HBI-8000: HUYA Bioscience International
*
AT-104: Applied Therapeutics
*
Auto 5: Autolus
*
AK 104: Akeso Biopharma
*
Tolinapant: Astex Pharmaceuticals
*
Duvelisib: Secura Bio
*
Lacutamab: Innate Pharma
*
AZD 4205: Dizal Pharmaceutical
*
Mitoxantrone liposomal: CSPC ZhongQi Pharmaceutical Technology
Peripheral T Cell Lymphomas Route of Administration
Peripheral T Cell Lymphomas pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Subcutaneous
*
Intravenous
*
Oral
*
Intramuscular
*
Intra-tumoral
*
Molecule Type
Peripheral T Cell Lymphomas Molecule Type
Peripheral T Cell Lymphomas Products have been categorized under various Molecule types, such as
*
Monoclonal antibodies
*
Immunoglobulins
*
Small molecules
*
Pyrimidines
*
Proteins and Peptides
*
Product Type
Peripheral T Cell Lymphomas Pipeline Therapeutics Assessment
*
Peripheral T Cell Lymphomas Assessment by Product Type
*
Peripheral T Cell Lymphomas By Stage and Product Type
*
Peripheral T Cell Lymphomas Assessment by Route of Administration
*
Peripheral T Cell Lymphomas By Stage and Route of Administration
*
Peripheral T Cell Lymphomas Assessment by Molecule Type
*
Peripheral T Cell Lymphomas by Stage and Molecule Type
DelveInsight's Peripheral T Cell Lymphomas Report covers around 40+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Peripheral T Cell Lymphomas product details are provided in the report. Download the Peripheral T Cell Lymphomas pipeline report to learn more about the emerging Peripheral T Cell Lymphomas therapies [https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphomas-ptcl-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Peripheral T Cell Lymphomas Therapeutics Market include:
Key companies developing therapies for Peripheral T Cell Lymphomas are - Celleron Therapeutics, Myeloid Therapeutics, Astex Pharmaceuticals, Citius Pharmaceuticals, Innate Pharma, Secura Bio, Genor Biopharma Co., Ltd., CerRx, Inc., Dizal Pharmaceuticals, Kura Oncology, Inc., Viracta Therapeutics, Autolus Therapeutics, Affimed Therapeutics, C4 Therapeutics, Kymera Therapeutics, Daiichi Sankyo, SciTech Development LLC, Sorrento Therapeutics, Bristol-Myers Squibb, Shanghai Yingli Pharmaceutical, Ono Pharmaceutical, and others.
Peripheral T Cell Lymphomas Pipeline Analysis:
The Peripheral T Cell Lymphomas pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Peripheral T Cell Lymphomas with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Peripheral T Cell Lymphomas Treatment.
*
Peripheral T Cell Lymphomas key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Peripheral T Cell Lymphomas Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Peripheral T Cell Lymphomas market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Peripheral T Cell Lymphomas drugs and therapies [https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphomas-ptcl-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Peripheral T Cell Lymphomas Pipeline Market Drivers
*
Increase in incidences of PTCL, rising investment for the development of advanced technologies, surge in government initiatives to promote research and awareness about the disease are some of the important factors that are fueling the Peripheral T Cell Lymphomas Market.
Peripheral T Cell Lymphomas Pipeline Market Barriers
*
However, high cost associated with the treatment, lack of skilled professionals for early diagnosis of the disease and other factors are creating obstacles in the Peripheral T Cell Lymphomas Market growth.
Scope of Peripheral T Cell Lymphomas Pipeline Drug Insight
*
Coverage: Global
*
Key Peripheral T Cell Lymphomas Companies: HUYA Bioscience International, Applied Therapeutics, Autolus, Akeso Biopharma, Astex Pharmaceuticals, Secura Bio, Innate Pharma, Dizal Pharmaceutical, CSPC ZhongQi Pharmaceutical Technology, and others
*
Key Peripheral T Cell Lymphomas Therapies: HBI-8000, AT-104, Auto 5, AK 104, Tolinapant, Duvelisib, Lacutamab, AZD 4205, Mitoxantrone liposomal, and others
*
Peripheral T Cell Lymphomas Therapeutic Assessment: Peripheral T Cell Lymphomas current marketed and Peripheral T Cell Lymphomas emerging therapies
*
Peripheral T Cell Lymphomas Market Dynamics: Peripheral T Cell Lymphomas market drivers and Peripheral T Cell Lymphomas market barriers
Request for Sample PDF Report for Peripheral T Cell Lymphomas Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphomas-ptcl-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Peripheral T Cell Lymphomas Report Introduction
2. Peripheral T Cell Lymphomas Executive Summary
3. Peripheral T Cell Lymphomas Overview
4. Peripheral T Cell Lymphomas- Analytical Perspective In-depth Commercial Assessment
5. Peripheral T Cell Lymphomas Pipeline Therapeutics
6. Peripheral T Cell Lymphomas Late Stage Products (Phase II/III)
7. Peripheral T Cell Lymphomas Mid Stage Products (Phase II)
8. Peripheral T Cell Lymphomas Early Stage Products (Phase I)
9. Peripheral T Cell Lymphomas Preclinical Stage Products
10. Peripheral T Cell Lymphomas Therapeutics Assessment
11. Peripheral T Cell Lymphomas Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Peripheral T Cell Lymphomas Key Companies
14. Peripheral T Cell Lymphomas Key Products
15. Peripheral T Cell Lymphomas Unmet Needs
16 . Peripheral T Cell Lymphomas Market Drivers and Barriers
17. Peripheral T Cell Lymphomas Future Perspectives and Conclusion
18. Peripheral T Cell Lymphomas Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=peripheral-t-cell-lymphomas-pipeline-assessment-2024-therapies-clinical-trials-and-key-companies-involved-by-delveinsight-celleron-therapeutics-myeloid-therapeutics-astex-pharma-citius-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Peripheral T Cell Lymphomas Pipeline Assessment 2024: Therapies, Clinical Trials, and Key Companies Involved by DelveInsight | Celleron Therapeutics, Myeloid Therapeutics, Astex Pharma, Citius Pharma here
News-ID: 3814634 • Views: …
More Releases from ABNewswire

"Faces of Psychosis" Redefines Art and Memoir with Unflinching Vision
Image: https://www.abnewswire.com/upload/2025/09/0dee09b98e12efa62723aec52dbb43c5.jpg
Shoreline, WA - Jairus Beane's Faces of Psychosis has ignited critical acclaim as a genre-defying masterpiece that fuses memoir, avant-garde photography, and mental health advocacy. Released today, the groundbreaking work, featuring 92 unaltered hallucinatory images, such as the visceral "Horror Strip" (page 95) and the abstract "Cotton Picasso" (page 92), positions Beane alongside visionaries like Yayoi Kusama and Frida Kahlo in transforming psychological turmoil into transcendent art. Galleries from…

Europe Payments Market Forecast to Reach USD 1.31 Trillion by 2030, Driven by Di …
Mordor Intelligence has published a new report on the Europe payments market, offering a comprehensive analysis of trends, growth drivers, and future projections.
Europe Payments Market Overview
The Europe payments market size stood at USD 0.64 trillion in 2025 and is projected to double to USD 1.31 trillion by 2030, reflecting a brisk 15.23% CAGR. This growth is fueled by a steady shift from cash to digital payments, rising adoption of mobile…

A Gentle New Book Welcomes Babies With the Words Every Child Deserves to Hear
There's a certain kind of quiet magic in those first moments with a new baby, the soft weight of their body, the deep stillness of their sleep, the questions that swirl in your heart. In her newest children's book, The Book God Makes for You Before You Are Born , author and educator Christie Rodgers captures that sacred tenderness and puts it into words.
Written as a gentle poem filled with…

The Lighted by Eugenie Giasson Illuminates a Story of Truth, Family, and Miracle …
In a world where lies thrive in darkness, author Eugenie Giasson delivers a luminous new novel, The Lighted , a sweeping story that reminds us that truth will always find a way to shine.
The journey begins in 1998, in a modest ceramic studio in Cape Cod. An elderly artist, Abel Smith, spends his final years creating seven extraordinary lamps-hand-sculpted figures of expectant mothers, adorned with silk, pearls, and crystals. To…
More Releases for Peripheral
Peripheral Vascular Devices Market - Advancing vascular health: Cutting-edge dev …
Newark, New Castle, USA: The "Peripheral Vascular Devices Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Peripheral Vascular Devices Market: https://www.growthplusreports.com/report/peripheral-vascular-devices-market/7820
This latest report researches the industry structure,…
Peripheral Stent Market - Pioneering Solutions for Peripheral Artery Disease: Re …
Newark, New Castle, USA - Growth Plus Reports has published a new report on Peripheral Stent Market, which includes a detailed analysis based on competitors and important market segments (2023-2031). The Global Peripheral Stent provides a thorough analysis of many segments such as opportunities, market size, developments, innovation, sales, and overall growth of leading players. The research is based on primary and secondary statistical data, and it includes both intuitive…
Peripheral Vascular Devices Market - Empowering Mobility, Preserving Health: Ele …
Newark, New Castle, USA - new report, titled Peripheral Vascular Devices Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Peripheral Vascular Devices market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Peripheral Vascular Devices market. The report offers an overview of…
Peripheral Vascular Devices Market Report 2018: Segmentation by Types (Periphera …
Global Peripheral Vascular Devices market research report provides company profile for Abbott Vascular, Bayer Healthcare, Volcano Corporation, Teleflex Medical and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to 2025, etc. The report also provides detailed segmentation…
Peripheral Vascular Device Market Size, Peripheral Vascular Device Market Share, …
Global Peripheral Vascular Device Market Size is observed to gain traction owing to the factors such as increasing research and development for developing several new product, and rising funding by the private organizations.
Request for Sample of This Research Report @ https://bit.ly/2xjOKpC
Top Key Player:-
Abbott Laboratories
Braun Melsungen AG
Boston Scientific Corporation
R. Brad, Inc.
Cardinal Health, Inc.
Medtronic plc.
Cook Medical, Inc.
Teruma Corporation
Jude Medical, Inc.
The Spectranetics Corporation
Volcano Corporation
Peripheral vascular disorder (PVD) is a blood circulation disorder…
Peripheral Artery Disease Market By Type (Peripheral Angioplasty Balloons, Perip …
Peripheral artery disease is characterized by plaque built up in the arteries carrying blood from heart to legs, arms, and other limbs. Peripheral artery disease in turn also increases the risk of other cardiovascular disorders such as heart attack, coronary heart disease, stroke, and ischemic attack.
Request Sample At: https://www.bigmarketresearch.com/request-sample/1633533
The global peripheral artery disease market generated $3,136 million in 2016, and is projected to reach $4,980 million by 2023, registering a…